Previous Close | 20.56 |
Open | 20.62 |
Bid | 20.50 x 100 |
Ask | 20.67 x 100 |
Day's Range | 20.32 - 20.88 |
52 Week Range | 20.32 - 79.65 |
Volume | |
Avg. Volume | 657,135 |
Market Cap | 1.104B |
Beta (5Y Monthly) | 0.24 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.76 |
Earnings Date | Apr 29, 2024 - May 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 66.77 |
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.